Tyrell Rivers

Dr. Rivers is Executive Director of Corporate Development & Ventures at AstraZeneca, where he is responsible for creating and executing innovative, value-enhancing business strategies. Prior to assuming this role in 2014, he worked at MedImmune Ventures, specializing in biotechnology investing. Earlier in his career, Dr. Rivers held various positions at Merck & Co., where he led technical support for commercial vaccines and directed global business initiatives for assessing key technologies for research and development. He currently serves as a Board member of ADC Therapeutics, Cerapedics, Goldfinch Bio, and VaxEquity. Dr. Rivers holds his B.S. in Chemical Engineering from the Massachusetts Institute of Technology, a Ph.D. in Chemical Engineering from the University of Texas at Austin, and an M.B.A. from the New York University Stern School of Business.